Calidi Biotherapeutics, Inc.
Business
Calidi Biotherapeutics develops targeted cancer therapies using engineered oncolytic viruses to deliver genetic medicines to tumor sites. The company's RedTail platform employs an enveloped vaccinia virus for systemic delivery, with lead candidate CLD-401 delivering IL-15 superagonist to the tumor microenvironment. Legacy platforms SuperNova and NeuroNova use stem cell-based approaches for solid tumors and glioma. The company operates through internal development, contract manufacturing partnerships, and license agreements with academic institutions.
Summary from 10-K filed 2026-03-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | −10 | −9 | −13 | −7 | |
| General and administrative | −11 | −13 | −16 | −16 | |
| Total operating expense | −20 | −22 | −29 | −23 | |
| Loss from operations | −20 | −22 | −29 | −23 | |
| Change in fair value of other liabilities and derivatives | 1,000 | 285,000 | — | — | |
| Change in fair value of other liabilities and derivatives related party | 1,000 | 39,000 | — | — | |
| Grant income | 50,000 | 181,000 | 3 | — | |
| Gain on sale of investment in Nova Cell | 244,000 | — | — | — | |
| Other income, net | 103,000 | 9,000 | −51,000 | −5,000 | |
| Total other income (expenses), net | 192,000 | −419,000 | −208,000 | −2 | |
| LOSS BEFORE INCOME TAXES | −20 | −22 | −29 | −25 | |
| Income tax provision | −15,000 | −14,000 | −16,000 | −11,000 | |
| NET LOSS | −20 | −22 | −29 | — | |
| Net loss attributable to noncontrolling interest | −157,000 | −66,000 | — | — | |
| NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST | −20 | −22 | −29 | −25 | |
| Deemed dividend on warrants | −6 | −2 | — | — | |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | −26 | −24 | −29 | — | |
| Net loss per share, basic | −5.95 | −35.7 | −17.33 | 2.99 | |
| Net loss per share, diluted | −5.95 | −35.7 | −17.33 | 2.99 | |
| Weighted average common shares outstanding, basic | 4,302 | 667 | 2 | 9 | |
| Weighted average common shares outstanding, diluted | 4,302 | 667 | 2 | 9 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 6 | 10 | 2 | 372,000 | 1 | |
| Prepaid expenses and other current assets | 656,000 | 636,000 | 2 | 414,000 | — | |
| Total current assets | 6 | 10 | 4 | 786,000 | 1 | |
| Machinery and equipment, net | 781,000 | 869,000 | — | — | — | |
| Operating lease right-of-use assets, net | 2 | 3 | 4 | 199,000 | — | |
| Other noncurrent assets | 138,000 | 152,000 | 373,000 | 725,000 | — | |
| TOTAL ASSETS | 9 | 14 | 10 | 3 | 232 | |
| Finance lease liability, current | 111,000 | 66,000 | 81,000 | 72,000 | — | |
| Operating lease right-of-use liability, current | 1 | 1 | 1 | 44,000 | — | |
| Total current liabilities | 4 | 9 | 10 | 43 | 410,985 | |
| Operating lease right-of-use liability, noncurrent | 277,000 | 2 | 3 | 305,000 | — | |
| Finance lease liability, noncurrent | 171,000 | 145,000 | 216,000 | 142,000 | — | |
| Promissory note | 600,000 | 600,000 | — | — | — | |
| Warrant liability | 107,000 | 119,000 | 623,000 | — | — | |
| Related party warrant liability | 8,000 | 9,000 | 48,000 | — | — | |
| TOTAL LIABILITIES | 5 | 12 | 18 | 43 | 16 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Common stock, $0.0001 par value, 330,000 shares authorized; 7,217 and 1,730 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1,000 | — | 1,000 | 2,000 | — | |
| Additional paid-in capital | 145 | 123 | 91 | 20 | 0 | |
| Accumulated other comprehensive loss, net of tax | −13,000 | −28,000 | −47,000 | −14,000 | — | |
| Accumulated deficit | −142 | −122 | −100 | −70 | −15 | |
| Total stockholders equity | 4 | 2 | −8 | −50 | −32 | |
| Noncontrolling interest | — | 434,000 | — | — | — | |
| Total equity | 4 | 2 | −8 | −50 | — | |
| TOTAL LIABILITIES AND TOTAL EQUITY | 9 | 14 | 10 | 3 | 232 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Depreciation and amortization expense | 2 | 2 | — | — | |
| Amortization of debt discount and financing costs | — | 45,000 | 432,000 | 123,000 | |
| Stock-based compensation | 2 | 3 | 5 | 5 | |
| Change in fair value of other liabilities and derivatives | −2,000 | −324,000 | — | — | |
| Prepaid expenses and other current assets | −42,000 | 2 | −2 | 170,000 | |
| Accounts payable | −1 | −628,000 | −6 | 2 | |
| Accrued expenses and other current liabilities | −2 | −2 | 1 | 2 | |
| Operating lease right of use liability | −1 | −1 | −628,000 | — | |
| Net cash used in operating activities | −21 | −20 | −27 | −13 | |
| Purchases of machinery and equipment | −120,000 | −16,000 | −585,000 | −428,000 | |
| Cash disposed in sale of investment in Nova Cell | −50,000 | — | — | — | |
| Net cash used in investing activities | −170,000 | −16,000 | −478,000 | −494,000 | |
| Proceeds from public offerings | 10 | 14 | — | — | |
| Proceeds from warrant inducement financing | 4 | 2 | — | — | |
| Proceeds from registered direct offering | 4 | — | — | — | |
| Proceeds from at the market offering | 3 | 3 | — | — | |
| Proceeds from exercise of pre-funded warrants | 5,000 | 2,000 | — | — | |
| Repayment of financing lease obligations | −90,000 | −82,000 | −101,000 | −81,000 | |
| Repayment of principal on term notes payable | −200,000 | −300,000 | −1 | −38,000 | |
| Repayment of principal on related party bridge loan payable | −200,000 | — | — | — | |
| Payment of financing costs | −846,000 | −2 | −2 | −58,000 | |
| Repayment of principal on related party term notes payable | −2 | — | — | — | |
| Proceeds from issuance of noncontrolling interest in Nova Cell | — | 2 | — | — | |
| Proceeds from issuance of convertible notes payable | — | 3 | — | — | |
| Related party proceeds from issuance of loan payable | — | 200,000 | — | 3 | |
| Proceeds from issuance of promissory note | — | 600,000 | — | — | |
| Proceeds from issuance of common stock and warrants per subscription agreement | — | 1 | — | — | |
| Proceeds from exercise of common stock warrants | — | 5 | — | — | |
| Repayment of convertible note payable | — | −2 | — | — | |
| Payment of debt issuance costs | — | −9,000 | — | — | |
| Net cash provided by financing activities | 17 | 27 | 29 | 12 | |
| Effect of exchange rate changes on cash | 14,000 | −13,000 | −6,000 | — | |
| NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH | −4 | 8 | 2 | −968,761 | |
| Cash paid for interest | 1 | 140,000 | 404,000 | 35,000 | |
| Cash paid for income taxes | 17,000 | 14,000 | — | — | |
| Machinery and equipment acquired through financing leases | 152,000 | — | 180,000 | 198,000 | |
| Financing fees included in accounts payable and accrued liabilities | 27,000 | −91,000 | — | — | |
| Issuance of common stock per conversion of convertible note | — | 3 | — | — | |
| Issuance of convertible note for legal settlement | — | 2 | — | — | |
| Issuance of common stock in lieu of cash for services | — | 289,000 | — | 205,000 | |
| Related party issuance of common stock in lieu of cash for services | — | 80,000 | — | — | |
| Issuance of common stock and warrants for legal settlement | — | 308,000 | — | — | |
| Debt discount on Convertible Notes | — | 109,000 | — | — | |
| Issuance of common stock in lieu of cash for SEPA commitment fee | — | 81,000 | — | — | |
| Issuance of restricted stock units for liability settlement | — | 133,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Calidi Biotherapeutics, Inc.'s CIK number?
Calidi Biotherapeutics, Inc.'s SEC CIK number is 0001855485 (1855485). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Calidi Biotherapeutics, Inc.'s SEC filings?
All of Calidi Biotherapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Calidi Biotherapeutics, Inc. last report earnings?
Calidi Biotherapeutics, Inc. (CLDWW) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-023094). This is Calidi Biotherapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Calidi Biotherapeutics, Inc.'s most recent earnings 8-K?
Calidi Biotherapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001493152-26-023094. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Calidi Biotherapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →